LMLidia Mosyak

Lidia Mosyak

*This is an algorithmically generated author record based on publicly available information.

Lidia Mosyak has a total of 46 co-authors. Here are the top co-authors by number of shared publications:

  • Madhavan Buddha

    Department of Chemical and Screening Sciences, Wyeth Research, 200 Cambridge Park Drive, Cambridge, MA 02140, USA

    2 shared publications
  • Ron Kriz

    Department of Chemical and Screening Sciences, Wyeth Research, 200 Cambridge Park Drive, Cambridge, MA 02140, USA

    2 shared publications
  • Xiaotian Zhong

    Department of Chemical and Screening Sciences, Wyeth Research, Cambridge, Massachusetts 02140, USA

    2 shared publications
  • Andrew Wood

    Wyeth Research 08852 Princeton New Jersey

    1 shared publication
  • Ann Aulabaugh

    Wyeth Research 10965 Pearl River New York

    1 shared publication
  • Bethany Freeman

    Department of Biological Technologies, Wyeth Research, Cambridge, Massachusetts 02140, USA

    1 shared publication

Latest Publications

  • Expression, purification and crystallization of the ecto-enzymatic domain of rat E-NTPDase1 CD39

    by Xiaotian Zhong, Madhavan Buddha, Guido Guidotti, Ron Kriz, Will Somers, Lidia Mosyak

    CD39 is a prototype member of the ecto-nucleoside triphosphate diphosphohydrolase family that hydrolyzes extracellular nucleoside diphosphates and triphosphates in the presence of divalent cations. Here, the expression, purification and crystallization of the ecto-enzymatic domain of rat CD39, sCD39, are described. The 67 kDa secreted soluble glycoprotein was recombinantly overexpressed in a glycosylation mutant CHO line, Lec.3.2.8.1, and purified from conditioned media. Diffraction-quality crystals of sCD39 were produced by the vapor-diffusion method using PEG 3350 and ammonium dihydrogen phosphate as precipitants. The enzyme crystallized in a primitive trigonal form in space group P3(2), with unit-cell parameters a = b = 118.1, c = 81.6 A and with two sCD39 copies in the asymmetric unit. Several low- to medium-resolution diffraction data sets were collected using an in-house X-ray source. Analysis of the intensity statistics showed that the crystals were invariably merohedrally twinned with a high twin fraction. For initial phasing, a molecular-replacement search was performed against the complete 3.2 A data set using a maximum-likelihood molecular-replacement method as implemented in Phaser. The initial model of the two sCD39 monomers was placed into the P3(2) lattice and rigid-body refined and position-minimized with PHENIX.


  • Crystal structures of the two major aggrecan degrading enzymes, ADAMTS4 and ADAMTS5

    by Lidia Mosyak, Katy Georgiadis, Tania Shane, Kristine Svenson, Tracy Hebert, Thomas McDonagh, Stewart Mackie, Stephane Olland, Laura Lin, Xiaotian Zhong, et al.

    Aggrecanases are now believed to be the principal proteinases responsible for aggrecan degradation in osteoarthritis. Given their potential as a drug target, we solved crystal structures of the two most active human aggrecanase isoforms, ADAMTS4 and ADAMTS5, each in complex with bound inhibitor and one wherein the enzyme is in apo form. These structures show that the unliganded and inhibitor-bound enzymes exhibit two essentially different catalytic-site configurations: an autoinhibited, nonbinding, closed form and an open, binding form. On this basis, we propose that mature aggrecanases exist as an ensemble of at least two isomers, only one of which is proteolytically active.


  • Structure-based optimization of PKCθ inhibitors

    by L. Mosyak, Z. Xu, D. Joseph-McCarthy, N. Brooijmans, W. Somers, D. Chaudhary

    PKCθ (protein kinase Cθ) is a central signalling molecule in the T-cell receptor activation pathway and is a target for treatment of a number of diseases. Several PKC inhibitors are in the drug-discovery pharmaceutical programmes today for the treatment of cancer, diabetes and arthritis. CD4+ T-lymphocytes also play a critical role in the initiation and progression of allergic airway inflammation. Our goal is the development of PKCθ antagonists as a means to control asthma and autoimmune diseases, using the strategy based on developing small-molecule agents that would block the enzyme's catalytic activity. Here, we discuss our work on the discovery of lead chemical series and review our X-ray structural and modelling approaches, including a structure-surrogate strategy that helped guide us in the lead compound optimizations.


  • Open Access

    The Structure of the Lingo-1 Ectodomain, a Module Implicated in Central Nervous System Repair Inhibition

    by Lidia Mosyak, Andrew Wood, Brian Dwyer, Madhavan Buddha, Mark Johnson, Ann Aulabaugh, Xiaotian Zhong, Eleonora Presman, Susan Benard, Kerry Kelleher, et al.